Takeda Pharmaceutical Co. (NYSE:TAK) Shares Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. increased its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 88.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 396,833 shares of the company's stock after buying an additional 186,349 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Takeda Pharmaceutical were worth $5,901,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC purchased a new position in Takeda Pharmaceutical during the 1st quarter worth approximately $37,000. Farther Finance Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after purchasing an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. purchased a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at approximately $52,000. EverSource Wealth Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock valued at $69,000 after purchasing an additional 1,770 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in shares of Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after purchasing an additional 2,411 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded down $0.17 during trading on Friday, reaching $14.67. The company's stock had a trading volume of 3,165,167 shares, compared to its average volume of 2,003,766. The company has a quick ratio of 0.52, a current ratio of 1.01 and a debt-to-equity ratio of 0.57. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $15.53. The company has a market capitalization of $46.68 billion, a P/E ratio of 66.68 and a beta of 0.23. The business has a 50 day moving average price of $14.84 and a 200-day moving average price of $14.38.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. The business had revenue of $7.34 billion during the quarter, compared to analysts' expectations of $8.02 billion. As a group, sell-side analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.